Evommune, Inc. (EVMN): R&D Expense

Annual figures by period end, from SEC filings.

$74.04M

Year ended 2025-12-31

$83.77M

Trailing 12 months to 2026-06-30

2024-12-31 R&D Expense (USD) 2025-12-31

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$74.04M	+15.3%	2026-03-05, From 2025-01-01
2024-12-31	$64.24M	n/a	2026-03-05, From 2024-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
Evommune, Inc. (EVMN)	2025-12-31	$74.04M	+15.3%
Tonix Pharmaceuticals Holding Corp. (TNXP)	2025-12-31	$44.49M	+11.3%
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	$313.0K	-52.4%
CV Sciences, Inc. (CVSI)	2025-12-31	$122.0K	+3.4%
Pyxis Oncology, Inc. (PYXS)	2025-12-31	$73.70M	+25.4%
Prelude Therapeutics Inc (PRLD)	2025-12-31	$94.30M	-20.1%
Arbutus Biopharma Corp (ABUS)	2025-12-31	$25.24M	-53.3%
Opus Genetics, Inc. (IRD)	2025-12-31	$30.81M	+14.8%
Jaguar Health, Inc. (JAGX)	2025-12-31	$24.97M	+50.9%

Compare EVMN, TNXP, EMMA, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗